CSPC Innovation Pharmaceutical Co., Ltd. (300765.SZ)
- Previous Close
52.59 - Open
49.06 - Bid 51.56 x --
- Ask 51.65 x --
- Day's Range
51.11 - 60.00 - 52 Week Range
21.07 - 60.00 - Volume
15,684,515 - Avg. Volume
10,531,214 - Market Cap (intraday)
72.912B - Beta (5Y Monthly) 0.28
- PE Ratio (TTM)
-- - EPS (TTM)
-0.05 - Earnings Date Apr 23, 2025
- Forward Dividend & Yield 0.02 (0.04%)
- Ex-Dividend Date May 29, 2025
- 1y Target Est
45.48
CSPC Innovation Pharmaceutical Co., Ltd. engages in the research and development, production, and sales of biopharmaceuticals, APIs, and functional foods in China and internationally. It offers functional raw ingredients, including caffeine, acarbose, anhydrous glucose, theophylline, aminophylline, dihydroxyphylline, theobromine, pentoxifylline, doxofylline, and raw enzymes; and health food products, such as Guoweikang Vitamin C tablets, Guoweikang B vitamin lozenges, etc. The company was founded in 2006 and is headquartered in Shijiazhuang, China. CSPC Innovation Pharmaceutical Co., Ltd. is a subsidiary of CSPC NBP Pharmaceutical Co., Ltd.
www.xnwpharma.net2,487
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: 300765.SZ
View MorePerformance Overview: 300765.SZ
Trailing total returns as of 5/30/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 300765.SZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 300765.SZ
View MoreValuation Measures
Market Cap
73.87B
Enterprise Value
72.57B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
39.73
Price/Book (mrq)
19.93
Enterprise Value/Revenue
37.63
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-2.71%
Return on Assets (ttm)
-4.62%
Return on Equity (ttm)
-9.67%
Revenue (ttm)
1.93B
Net Income Avi to Common (ttm)
-52.24M
Diluted EPS (ttm)
-0.05
Balance Sheet and Cash Flow
Total Cash (mrq)
1.3B
Total Debt/Equity (mrq)
0.01%
Levered Free Cash Flow (ttm)
-515.03M